Intellia Therapeutics Inc

NASDAQ:NTLA  
130.59
-1.18 (-0.90%)
Products

Intellia Reports U.S. FDA Acceptance Of IND Application For Its Candidate For Acute Myeloid Leukemia

Published: 09/16/2021 11:48 GMT
Intellia Therapeutics Inc (NTLA) - Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for Ntla-5001, Its Crispr/cas9-engineered Tcr-t Cell Candidate for Acute Myeloid Leukemia.
Intellia Therapeutics Inc - Initiation of Patient Screening in Phase 1/2a Study of Ntla-5001 Expected by Year-end.
Intellia Therapeutics Inc - Has Also Submitted a Regulatory Application to Uk for Ntla-5001.